Table 2.
Effects of NOP-related agonists in NHPs in comparison with MOP agonists
| Intrathecal delivery | Analgesia | Itch | References | ||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| MOP receptor agonist | |||||||
| Morphine | ✓ | ✓ | [124, 125] | ||||
| Selective NOP receptor agonist | |||||||
| N/OFQ | ✓ | − | [94, 95] | ||||
| UFP-112 | ✓ | − | [65] | ||||
| PWT2-N/OFQ | ✓ | − | [107] | ||||
| Mixed NOP/MOP agonist | |||||||
| [Dmt1]N/OFQ(1–13)-NH2 | ✓ | ✓ | [120] | ||||
| PWT2-[Dmt1]N/OFQ(1–13)-NH2 | ✓ | − | [121] | ||||
| BU10038 | ✓ | − | [69] | ||||
| Mixed NOP/MOP full agonist | |||||||
| Cebranopadol | ✓ | − | [170] | ||||
|
| |||||||
| Systemic delivery | Analgesia | Abuse potential | Respiration depression | Physical dependence | Itch | Sedation | References |
|
| |||||||
| MOP receptor agonist | |||||||
| Oxycodone | ✓ | + + + | N.D. | ✓ | ✓ | − | [124, 151, 152] |
| Fentanyl | ✓ | + + + | ✓ | N.D. | ✓ | − | [145, 170, 174] |
| Heroin | ✓ | + + + | ✓ | ✓ | N.D. | − | [8, 155, 173] |
| Selective NOP receptor agonist | |||||||
| Ro 64–6198 | ✓/− | − | − | N.D. | − | ✓ | [60, 139, 172] |
| SCH 221510 | ✓ | N.D. | − | − | − | N.D. | [64, 143, 145] |
| Mixed NOP/MOP partial agonist | |||||||
| BU08028 | ✓ | − | − | − | − | − | [145] |
| AT-121 | ✓ | − | − | − | − | − | [155] |
| BU10038 | ✓ | − | − | − | − | − | [69] |
| Mixed NOP/MOP full agonist | |||||||
| Cebranopadol | ✓ | + | − | N.D. | − | − | [170] |
(✓) detected, (−) not detected, (+++/+) degree of abuse potential, N.D. not determined